MDGL PEER ANALYSIS

Madrigal Pharmaceuticals Inc — metric-by-metric comparison with peers and the industry median

MDGLMadrigal Pharmaceuticals Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value itDuel

Overall Profile & Returns

· Biotechnology

Position Within Industry

0 = weak quartile, 100 = strong quartile
ValuationProfitabilityGrowthFinancial Health
MDGLIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year
Split-adjusted
MDGL+75.9%CSL-48.2%TLX-29.5%MSB+27.6%
Year-to-Date (YTD)
MDGL-9.3%CSL-28.5%TLX+50.7%MSB-24.3%

Key Metric Comparison

P/E

Lower is better
MDGLCSL29.44TLXMSBMedian 17.91

ROE

Higher is better
MDGL-49.3%CSL7.7%TLX-1.8%MSB-11.3%Median -47.5%

Net Margin

Higher is better
MDGL-27.3%CSL9.2%TLX-0.9%MSB-115.3%Median -125.7%

Revenue Growth

Higher is better
MDGL256.8%CSL4.8%TLX56.3%MSB410.4%Median 5.1%

All Metrics

Valuation
MetricMDGLCSLTLXMSBInd. Median
P/E29.4417.91
P/B28.212.206.373.51
EV/EBITDA10.21120.1414.82
P/S13.542.623.2431.6110.89
Financial Health
MetricMDGLCSLTLXMSBInd. Median
Current Ratio3.502.571.435.90
Debt/Equity63.9%67.4%112.3%10.9%
NetDebt/EBITDA1.672.2213.131.15
Profitability
MetricMDGLCSLTLXMSBInd. Median
Net Margin-27.3%9.2%-0.9%-115.3%-125.7%
ROE-49.3%7.7%-1.8%-11.3%-47.5%
ROA-27.8%3.8%-0.7%-8.6%-35.8%
EBITDA Margin-24.8%32.8%3.0%-76.6%-105.8%
Growth + Dividend
MetricMDGLCSLTLXMSBInd. Median
Rev. Growth256.8%4.8%56.3%410.4%5.1%
NI Growth-39.4%12.1%
Div. Yield2.5%0.0%0.2%
Payout103.1%0.0%0.0%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on MDGL

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.